Catalyst Pharma (CPRX) Stock Statistics & Valuation Metrics

Catalyst Pharma has a market cap or net worth of $3.03B. The enterprise value is $2.12B.

Catalyst Pharma has 121,959,175 shares outstanding. The number of shares has decreased by -2.65% in one year.

Catalyst Pharma’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 20.24%.

The current PE Ratio of Catalyst Pharma is 15.08. Catalyst Pharma’s PEG ratio is 0.14.

In the last 12 months, Catalyst Pharma had revenue of 491.73M and earned 163.89M in profits. Earnings per share was 1.38.

In the last 12 months, operating cash flow was 239.81M and capital expenditures -556.00K, giving a free cash flow of 239.25M billion.

Catalyst Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Catalyst Pharma upcoming earnings date is May 7, 2025, TBA Not Confirmed.

Catalyst Pharma as a current ratio of 5.17, with Debt / Equity ratio of 0.44%

In the past 12 months, Catalyst Pharma has paid 52.37M in taxes.

Catalyst Pharma EV to EBITDA ratio is 10.03, with an EV/FCF ratio of 13.65.

Catalyst Pharma has $517.55M in cash and marketable securities with ― in debt, giving a net cash position of -$514.37M billion.

Gross margin is 84.10%, with operating margin of 39.68%, and net profit margin of 33.33%.

The average price target for Catalyst Pharma is $34.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy